Sélectionnez votre langue


At VISION, we aim to translate data into life-changing biologicals, for the benefit of local populations. VISION strategy relies on bridging up academic and non-academic practices, skills and resources between widening (WICs) and non-widening partnering countries to empower their R&I skills and environment. VISION has the will to enable the WICs scientific community to wisely identify and exploit the huge potential of research data that bear great promise for a biologics/mRNA vaccine development. Such an objective will not only allow WICs to keep pace with the rapidly changing vaccinology deployment, but it will also foster the discovery of innovative bioproducts and approaches, therefore consolidating WICs regional positioning in terms of R&D. Through VISION, the WICs partners will reinforce their intrinsic smart specialization orientations, given their strategic partnership with European and regional non-academic entities. Here, we aim to contribute more proactively to the local and regional innovation policies, by making VISION a spot of regional open innovation platforms, where academia, government, industry, and civil participants work together to drive structural changes far beyond the project scope. In doing so, VISION perfectly adheres to the vision and expectation of the WIC governments, which urges researchers to enhance the socio-economic impact of their research activities.


The project will pave the way to a local empowerment and impact through several key impact pathways. A direct impact is envisioned on academic and non-academic talents in the three WICs partners that will act as key actors and game changers in mRNA vaccine and biologics development and R&I empowerment. Through this newly established ecosystem, the economic sector, with an emphasis on R&I, will enable the creation of highly competitive business cores including start-ups. Other impact pathways are expected on policy making towards improving laws, policies and regulations/ethics pertaining to mRNA vaccines and biologics manufacturing in widening countries. Finally, based on open science and RRI, the general public will benefit from the implementation of a complete ecosystem of collaborative work between various stakeholders for the adoption of R&I concepts and the development of sustainable solutions for citizen health problems.

VISION Strategic Objectives

VISION intends to achieve its goals by creating a thriving and sustainable R&I environment, and by placing dedicated personnel as Talents at the center of a R&I strategy to sustainably foster scientific excellence with concrete beneficial socio-economic outcomes. In this endeavor, VISION will address the following Strategic Objectives (SO).

SO1. Increase R&I capabilities in Widening countries (WICs) to become a premium spot at capturing the economic and social benefits from scientific research. We will create a networking R&I think tank of experts from Widening (IPT, TK) and European (IP, CRG) excellence academic institutions, as well as private entities in Widening countries (CI, DA) and Europe (MER, QT). The consortium will produce a roadmap on activities and regulatory framework supporting a R&I system to bridge the existing gaps between discovery, development and validation of mRNA vaccines and biologics and unleash the potential to address pressing health challenges, while considering the current strengths and weaknesses of R&I support systems at partnering countries.

SO2. Place IPT in pole position as a Training Hub for R&I activities, bridging non-widening European academic and non-academic healthcare entities with their Widening counterparts. This will be achieved by setting up an efficient, high-performance, and sustainable Training platform with both seconded personnel and a dynamic set of human resources dedicated to training purposes and mentoring.

SO3. Promote a sustainable Widening R&D environment through continued mentoring and secondment of skilled young researchers. We will cultivate an ecosystem to foster data-driven research and innovation, market-oriented research, entrepreneurial spirit and a business development culture to ensure increased socio-economic impact. VISION will nurture a cross-sectoral ecosystem to drive the national health biotech R&I system into a smart specialization strategy, as well as updating, improving, and adapting R&I policies, regulation  and legislation at both the national and regional levels, with the goal to address the needs and expectations of the society

SO4. Instill a Responsible Research and Innovation (RRI) spirit among community members, by communicating to stakeholders and promoting an increased interaction with the society at large with a more effective contribution to communication and dissemination. A special focus will be devoted to ethics, open science and public engagement

WP Objectives

Implementing the VISION project will be conducted following the presented diagram in Figure 2 (see Excellence section). The project is designed to strengthen vaccine and biologics development and manufacturing in widening partners through the implementation of a capacity building program based on mobilities and training to tailor WICs talents with required skills. Within WP2, the Training Hub aims to provide appropriate modules to address in-demand and lifelong needs by matching intersectoral valances (WP2). Benchmarking and gap analysis will be performed in WP3 and WP4 to have an in-depth assessment of the gaps and capacities and make appropriate matchmaking among the participant competencies to implement a relevant secondment/intersectoral mobility schedule for the reinforcement of mRNA technologies and mastering preclinical and clinical studies according to international ethical and regulatory guidelines and frameworks (WP5). VISION will provide a perfect opportunity to set up intersectoral interactions to foster a favorable environment of translational research, biobusiness and development entrepreneurship (WP6) with the aim to foster the dynamics of socio-economic actors (new knowledge, new medicine practices, ethics, creation of new markets, general public). A well-defined management and decision schema (WP1) will ensure the continuous partners’ support to VISION with a smooth interaction and waterfall execution. Due consideration will be provided to synergistic actions and connection among the WPs to ensure an efficient consolidation of the WPs outcomes. Furthermore, through VISION, IPT will set up key measures to foster a favorable environment of translational research, biobusiness and development entrepreneurship (WP6), while sustainably maintaining VISION achievements at high performance levels within and beyond the project period. In addition, a separate work package will be dedicated to go further in the exploitation of the impact that communication and dissemination should create by targeting specifically, citizens, start ups, industries, policy makers and funding agencies and exploit new participatory tools to support the implementation of collaborative work which focus on sustainable solutions related to R&I (WP7).The VISION scheme is essentially promoting innovative inter-sectoral collaboration in R&I through a various and rich cross-sectoral exchange of staff, with a focus on widening partners. This diverse and heterogeneous consortia will hence develop an intersectoral talent circulation at the benefit of widening partners, allowing collaboration with each other and participating in mutual (academic vs non-academic and widening vs non-widening) learning exercises.



Widening Countries

Institut Pasteur de Tunis (IPT), Academic, Tunisia

Connect’Innov (CI), Non-Academic, Tunisia

Darnitsa DA), Non-Academic, Ukraine

Institute for Virology, Vaccines and Sera Torlak (TK), Academic, Serbia

Non-Widening Countries

Institut Pasteur (DARRI / CRT / Biomics) (IP), Academic, France

Centre for Genomic Regulation (CRG), Academic, Spain

Quantoom Biosciences (QT), Non-Academic, Belgium

Merck Life Science (MER), Non-Academic, France



13, place Pasteur, B.P. 74 1002 Tunis, Belvédère Tunisie

E-mail : info@pasteur.tn

Téléphone : +216 71783 022 / +216 71 843 755